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Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour in humans 
and is highly resistant to current treatment modalities. We have explored the combined 
treatment of the endoplasmic reticulum (ER) stress-inducing agent 2,5-dimethyl-
celecoxib (DMC) and TNF-related apoptosis-inducing ligand (TRAIL-WT) or the DR5-
specific TRAIL D269H/E195R variant as a potential new strategy to eradicate GBM cells 
using TRAIL-resistant and -sensitive GBM cells.
Methods
GBM cell lines were investigated for their sensitivity to TRAIL, DMC and combination of 
both agents. Cell viability was measured by MTS assay and apoptosis was assessed by 
Annexin V/PI and acridine orange staining. Caspase activation and protein expression 
levels were analysed with Western blotting. Death Receptor (DR) cell surface expression 
levels were quantified by flow cytometry. DR5 expression was increased in U87 cells by 
ectopic expression using a retroviral plasmid and survivin expression was silenced using 
specific siRNAs.
Results
We demonstrate that A172 expresses mainly DR5 on the cell surface and that these cells 
show increased sensitivity for the DR5-specific rhTRAIL D269H/E195R variant. In contrast, 
U87 cells show low DR cell surface levels and is insensitive via both DR4 and DR5. We 
determined that DMC treatment displays a dose-dependent reduction in cell viability 
against a number of GBM cells, associated with ER stress induction, as shown by the 
up-regulation of glucose-regulated protein 78 (GRP78) and CCAAT/-enhancer-binding 
protein homologous protein (CHOP) in A172 and U87 cells. The dramatic decrease in 
cell viability is not accompanied by a correspondent increase in Annexin V/PI or caspase 
activation typically seen in apoptotic or/and necrotic cells within 24 h of treatment. 
Although DMC did not affect DR5 expression in the GBM cells, it increased TRAIL-
induced caspase-8 activation in both TRAIL-sensitive and -resistant cells, indicating 
that DMC potentiates initiator caspase activation in these cells. In A172 cells, sub-toxic 
concentrations of DMC greatly potentiated TRAIL-induced apoptosis. Furthermore, 
DMC strongly reduced survivin expression in A172 and U87 cells and silencing of this anti-
apoptotic protein partially sensitized cells to TRAIL-induced apoptosis.
Conclusion
Our findings corroborate that DMC is a promising agent against GBM, and uncovers a 
potential synergistic cooperation with TRAIL in this highly malignant cancer.
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BACkGRound
Glioblastoma multiforme (GBM) has been classified as a WHO grade IV glioma. This type 
of tumour is the most common and aggressive of the glial tumours. Despite the available 
treatment modalities, consisting of surgical resection followed by a combination of 
radiation and chemotherapy, the median survival rate ranges from 12-15 months [1]. To 
improve the prognosis of GBM patients, novel therapies are therefore required.
TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, 
has previously been shown to be a promising anti-cancer therapeutic agent [2, 3] for 
its ability to induce apoptosis in a variety of tumour cells, without affecting normal cells 
[4, 5]. Trimeric recombinant human TRAIL (rhTRAIL) is able to induce apoptosis upon 
binding to either death receptor 4 (DR4, TRAIL-R1) or death receptor 5 (DR5, TRAIL-R2). 
TRAIL receptor-specific apoptosis-inducing variants have previously been generated, 
displaying enhanced affinity for either DR4 or DR5, resulting in more potent apoptosis 
induction in several tumour cells [6, 7]. Binding of TRAIL to its cognate death receptors 
triggers the establishment of the death-inducing signalling complex (DISC), composed 
of FAS-associated death domain (FADD) and pro-caspase-8. Upon DISC formation, the 
initiator pro-caspase-8 is processed into active caspase-8, which is able to either directly 
cleave effector caspases-3 and -7, or cleave Bid into truncated Bid (tBid). The latter results 
in the release of mitochondrial factors, including cytochrome c, subsequently leading to 
caspase-9 cleavage and further activation of effector caspases, resulting in irreversible 
apoptosis [8]. In general, GBM cells have been found to be highly resistant to TRAIL-
induced apoptosis due to a variety of reasons, such as moderate to low expression of DR4 
and DR5 [9, 10], the up-regulation of the anti-apoptotic proteins c-FLIP, Bcl-2 and survivin 
[9, 11-14], or the down-regulation of critical pro-apoptotic proteins such as caspase-8 and 
Bak [9, 12, 15, 16]. 
Recently, an increasing number of reports have shown the therapeutic relevance of 
inducers of endoplasmic reticulum (ER) stress in cancer, also as sensitizers for TRAIL-
based therapies [17-23]. ER stress can be triggered by alterations in normal ER function, 
such as the accumulation of unfolded, misfolded or excessive proteins, imbalances of 
lipids or glycolipids, or changes in the redox or ionic conditions within the ER lumen 
[24-26]. The ER stress inducer 2,5-dimethyl-celecoxib (DMC) is an analogue of the 
cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug (NSAID) 
celecoxib. At the molecular level, DMC lacks the COX-2 inhibitory function present in 
celecoxib, whereas the ER stress-activating potential is enhanced by DMC [27, 28]. DMC 
has also been shown to block cell proliferation in several tumour cell culture models 
[28, 29] and demonstrated anti-tumorigenic activity in vivo [29]. ER stress appears to 
be initiated within seconds after the addition of DMC to cultured cells, through the 
inhibition of the sarcoplasmic/ER calcium ATPase (SERCA) [27, 30, 31]. Consequently, 
an ER stress response (ESR) is triggered, which is characterized by the up-regulation 
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of ER molecular chaperones, including the pro-survival regulator glucose-regulated 
protein 78 (GRP78), therefore facilitating protein folding, translocation of polypeptides 
across the ER membrane, and the activation of transmembrane ER stress sensors [32]. 
Another ER stress indicator is the enhanced expression of the pro-apoptotic CCAAT/-
enhancer-binding protein homologous protein (CHOP) [33-36], which has been found 
to up-regulate DR5 expression in several cancer cell types [17-22, 37]. ER stress has also 
been reported to down-regulate anti-apoptotic proteins, including c-FLIP [17-20], Bcl-2 
[18, 37, 38] and survivin [18, 23]. Moreover, prolonged activation of ER stress can lead to 
the activation of caspase-4 [27, 36, 39] and -7 [28, 36] resulting in apoptosis.
In this study we have explored the ability of DMC to enhance TRAIL-induced apoptosis 
in GBM cells. We demonstrate that A172, but not U87, is sensitive for apoptosis induced by 
rhTRAIL, and especially for the DR5-specific TRAIL variant D269H/E195R. DMC was able to 
significantly reduce cell viability of several GBM cell lines. We show that both sub-toxic 
and toxic doses of DMC significantly enhance TRAIL-induced apoptosis in A172 cells. 
Taken together, DMC in combination with rhTRAIL appears to be a promising therapeutic 
approach for the treatment of a subset of GBM cells.
MATeRIAL s And MeThods
Cell lines and chemicals
Human glioblastoma cell lines A172, U87, SNB75 and U251 were obtained from the American 
Type Culture Collection (ATCC). Cells were cultured in DMEM with 4.5 g/L D-glucose 
(Gibco, Life Technologies) supplemented with 10% foetal calf serum, 100 units/mL 
penicillin and 100 µg/mL streptomycin in a humidified incubator at 37 °C containing 5% 
CO
2
. 2,5-Dimethyl-celecoxib (DMC) was produced as described earlier [40, 41]. Celecoxib 
(CXB) was purchased from Key Organics. DMC and CXB were both dissolved in DMSO; 
the control with only solvent (DMSO) showed no toxicity. RhTRAIL wild-type (WT), DR4-
specific TRAIL variant 4C7 and DR5-specific TRAIL variant D269H/E195R (amino acids 
114-281) were constructed and produced as described earlier [6, 7].
Cell viability and apoptosis assays
Cell viability was measured using the MTS assay, a colorimetric method in which viable 
cells reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium (MTS) to a formazan product. Cells were seeded in triplicate in 96-well 
plates at a cell density of 10,000 cells/well. After 24 h, cells were treated for 24 h with 
concentrations ranging from 0 to 250 ng/mL of rhTRAIL WT or D269H/E195R and/or 0 to 
100 µM DMC in a final volume of 0.15-0.2 mL; reagents and ligands were serially diluted 
in cell culture medium. Cells were incubated with the MTS reagent according to the 
manufacturer’s instructions (G3581, Promega). Cell viability was determined by measuring 
the absorption at 492 nm on a microplate reader (Thermo Labsystems).
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Apoptosis induction was measured using Annexin V-FITC and propidium iodide (PI) 
staining and quantified by flow cytometry. Cells were seeded in 6-well plates 24 h prior to 
treatment. The next day, cells were treated for 24 h with 0, 25 or 50 µM DMC. After treatment, 
cells were harvested and washed with calcium buffer (10.9 µM HEPES, 140 µM NaCl, 2.5 µM 
CaCl
2
). Cell pellets were resuspended in 60 µL calcium buffer complemented with 5 µL 
Annexin V-FITC (IQP-120F, IQ Products) and incubated for 20 minutes on ice. Cells were 
washed and resuspended in 0.5 µg/mL PI (P4170, Sigma Aldrich) diluted in calcium buffer and 
left on ice until analysis. Cells were analysed using a FACSCalibur flow cytometer (BD).
Visualisation of apoptosis was accomplished using acridine orange. Cells were seeded 
in triplicate in 96-well plates with 10,000 cells/well 24 h prior to treatment. Treatment 
consisted of rhTRAIL WT (0, 10 or 100 ng/mL), with or without DMC (0, 25 or 50 µM) as 
indicated. After 24 h incubation, cells were stained with 2 µL/well 10x diluted 1 mg/mL 
acridine orange solution and incubated for 10 minutes. Plates were spun down for 10 
minutes at 900 rpm. Fluorescence microscopy was used to determine the presence of 
apoptotic bodies and/or chromatin condensation.
western blotting
GBM cells were seeded in T25 culture flasks at a density of 750,000 cells/flask 24 h prior 
to treatment. For TRAIL-induced apoptosis, A172 cells were treated for 5 h and U87 for 
24 h, since apoptosis is induced quickly in A172 cells. Cells were treated with rhTRAIL WT 
(0, 10 or 100 ng/mL), with or without DMC (0, 25 or 50 µM). After treatment, cells were 
harvested and lysed using the M-PER Mammalian Protein Extraction Reagent (PIERCE, 
Thermo Scientific) with additional Protease Inhibitor Cocktail, EDTA-Free (100x; Thermo 
Scientific). Protein concentrations were determined using a Bradford assay (Bio-Rad 
Laboratories). Equal amounts of protein for each sample were loaded per lane on 
pre-cast 4-12% SDS-PAGE gels (Invitrogen) and transferred onto Immobilon-FL PVDF 
0.45 µm membranes (Millipore). Subsequently, the membranes were blocked for 1h at 
room temperature in blocking buffer (Rockland). Western Blot membranes were probed 
overnight at 4 °C. The following primary antibodies were used: caspase-3 (9662, 9661), 
caspase-8 (9746), caspase-9 (9501, 9508), c-FLIP (8510), CHOP (2895), PARP (9542) (Cell 
Signaling), COX-2 (160112, Cayman Chemical), GRP78 (sc-13968, Santa Cruz) and survivin 
(AF886, R&D Systems). Goat-α-mouse-IRDye (800CW; 926-32210 and 680; #926-32220) 
or goat-α-mouse-IRDye (800CW; 926-32211 and 680; #926-32221) secondary antibodies 
(Westburg) were used for detection using a LI-COR Odyssey Infrared Imaging System 
(Westburg). Membranes were probed with anti-β-actin (0869100, MP Biomedicals) to 
confirm equal loading.
TRAIL receptor expression analysis
GBM cells were harvested and washed with standard buffer (PBS/1% BSA). TRAIL receptor 
cell surface expression was determined using 10 µg/mL TRAIL-R1 (ALX-804-297), TRAIL-R2 
48
3
(ALX-804-298), TRAIL-R3 (ALX-804-344), TRAIL-R4 (ALX-804-299) (Alexis Biochemicals, 
Enzo Life Sciences.), DR5-01-1 (EXB-11-461, Exbio) or negative control mouse IgG1 (X0931, 
DAKO). Cells were incubated with primary antibodies for 1h. Subsequently, the cells were 
washed and incubated for 1h with R-phycoerythrin (PE) conjugated goat anti-mouse 
antibody (1010-09, Southern Biotech) or Alexa Fluor 488 conjugated goat anti-mouse 
antibody (A-11001, Invitrogen). Receptor cell surface expression was analysed using a 
FACSCalibur flow cytometer (BD).
Retroviral-based dR5 overexpresssion
DR5-TV1 was amplified from a plasmid (kindly provided by MSD) using forward 
(5’-agatctatggaacaacggggacagaacg-3’) and reverse (5’-cgcgaattcttaggacatggcagagt-3’) 
primers containing BglII and EcoRI restriction sites. The PCR product was cloned into 
pMSCV-tdTomato, a retrovirus expression system (kindly provided by prof. J.J. Schuringa). 
For the packaging of the retroviral particles, 2*106 HEK293 cells were plated in 94.0 mm cell 
culture dishes. The next day, cells were transfected with either pMSCV-tdTomato vector 
expressing DR5-TV1 or an empty vector, using CaCl
2
. After 24 h, the medium containing 
virus particles was harvested, filtered and added to U87 cells, which were plated the day 
before at a density of 0.25*106 U87 cells in wells of a 6-wells plate. The U87 cells were 
exposed to the viral particles for 48h after which the virus was removed and fresh medium 
was added. Mixed populations of U87-empty or U87-DR5 cells were cultured in DMEM 
with 4.5 g/L D-glucose (Gibco, Life Technologies) supplemented with 10% foetal calf 
serum, 100 units/mL penicillin, and 100 µg/mL streptomycin in a humidified incubator at 
37 °C containing 5% CO
2
. U87 transduced cells, containing constructs encoding tdTomato, 
were sorted using a fluorescent activated cell sorter.
RnA interference
A172 cells were seeded in 6-wells plates at a density of 200,000 cells/well. The next day, the 
subconfluent cultures were incubated with unsupplemented Optimem medium (Gibco, 
Life Technologies) and transfected with 133 nM survivin (sc-29499, Santa Cruz) or negative 
control small interfering RNA (siRNA) (SR-CL000-005, Eurogentec) using Oligofectamine 
Transfection Reagent (12252-011, Invitrogen) according to the manufacturer’s protocol. 
24 h after siRNA transfection, cells were seeded and treated as indicated for MTS assays 
(24 h treatment) or Western blot analysis (5 h treatment).
ResuLTs
A172 but not u87 cells are sensitive to TRAIL-induced apoptosis primarily via dR5
Analysis of receptor expression by flow cytometry revealed distinct differences in TRAIL 
receptor membrane expression levels of A172 and U87 cells (figure 1A). While A172 
cells express high levels of DR5, U87 cells showed significantly lower levels of surface 
DR5. DR4 expression was found to be low in A172 and it was undetectable in U87. Low 
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decoy receptor expression was also detected in A172 cells and absent in U87 cells. 
Since both A172 and U87 cells show distinct expression profiles of DR5 on the membrane 
and low or absent expression of DR4, these cells were exposed to different concentrations 
of rhTRAIL WT, and the previously described DR4-selective variant (rhTRAIL 4C7) [6, 7] 
and DR5-selective variant (rhTRAIL D269H/E195R) [6]. A172 cells showed a clear dose 
dependent sensitivity to rhTRAIL, when treated with either rhTRAIL WT or rhTRAIL 
D269H/E195R, but was completely resistant to rhTRAIL 4C7. The mutant D269H/E195R was 
more effective in reducing cell viability in A172 when compared to rhTRAIL WT. In contrast, 
figure 1. A172 cells are sensitive to TRAIL-induced apoptosis in a dose-dependent manner. (A) 
Cell surface expression of the various TRAIL receptors was determined on A172 and U87 cells using 
flow cytometry analysis and expressed as the Mean Fluorescence Intensity (MFI) ratio. (B) Western blot 
analysis of A172 and U87 cells treated with 0, 10 or 100 ng/mL rhTRAIL WT for 5 h or 24 h, respectively. 
β-actin serves as a loading control. (C) Viability of A172 and U87 cells was assessed after treatment with 
various concentrations (0-1000 ng/mL) of rhTRAIL WT, 4C7 or D269H/E195R for 24 h as measured by MTS 
assays. Error bars represent S.E.M. of three independent experiments.
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U87 cells were highly resistant to all rhTRAIL ligands (figure 1B). Afterwards, Western blot 
analysis was used to detect cleavage of caspases and PARP after treatment with 10 (low) 
or 100 (moderately high) ng/mL rhTRAIL WT. Since A172 cells proved to be TRAIL sensitive 
these cells were exposed to rhTRAIL WT for 5 h in order not to lose the cells due to massive 
cell death. The TRAIL resistant U87 cells were treated for 24 h. Accordingly, rhTRAIL WT 
exposure resulted in clear cleavage of caspase-8, -9, -3 and PARP in A172 cells, whereas 
in U87 cells, even upon treatment with 100 ng/mL rhTRAIL WT, no activation of these 
apoptotic-related proteins was observed (figure 1C). We then tested if the differential 
TRAIL-sensitivities observed in A172 and U87 could be explained by the differences at the 
level of surface DR5 expression, with low levels of death receptor expression in U87 cells 
causing the insensitivity to both rhTRAIL WT and rhTRAIL D269H/E195R.
ectopic overexpression of dR5 in u87 cells does not enhance TRAIL sensitivity
To investigate whether enhancement of DR5 expression could trigger TRAIL-induced 
apoptosis, U87 cells were transduced with either an empty retroviral vector (U87-control) 
or a vector expressing DR5 (U87-DR5). This vector contains the gene for tdTomato, 
allowing for the isolation of transduced tdTomato-positive cells by FACS sorting. DR5 
expression levels were determined by flow cytometry using TRAIL receptor-specific 
antibodies labelled with the Alexa Fluor 488 dye, since PE-labelled antibodies would 
result in overlapping emission spectra with tdTomato (figure 2A). Notably, a large shift 
in mean fluorescence intensity (MFI) levels was measured when Alexa Fluor 488 was used 
compared to previous results with the PE dye. Although the elevated surface levels of DR5 
in U87-DR5 cells is similar to the DR5 expression level observed in A172 cells, U87-DR5 cells 
did not show enhanced sensitivity to rhTRAIL WT or rhTRAIL D269H/E195R even at high 
concentrations of rhTRAIL (up to 1000 ng/mL) (figure 2B). These results indicate that DR5 
overexpression per se is not sufficient to sensitize U87 cells to TRAIL-induced apoptosis.
dMC decreases cell viability of GBM cells and enhances TRAIL-induced 
apoptosis in A172 cells
Next, we examined the potential of the ER stress inducer DMC alone and in combination 
with TRAIL across several GBM cell lines. We started by determining the effect of DMC on 
the cell viability of GBM cells. As shown in figure 3A, DMC was able to efficiently promote 
reduction in cell viability as measured by MTS in all the GBM cell lines studied. SNB75 cells 
showed the highest sensitivity to DMC, whereas U251, A172 and U87 cells were almost 
equally sensitive to DMC (figure 3A).
To evaluate if the DMC effects observed in these cells were correlated with the 
induction of apoptosis or necrosis, A172 and U87 cells were treated with either a sub-toxic 
(25 µM) or a moderate cytotoxic (50 µM) dose of DMC for 24 h and stained with Annexin 
V/PI, with Annexin V positive cells representing the apoptotic fraction. Figure 3B shows 
that the addition of a high concentration of DMC alone resulted in a minor increase in 
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Annexin V positivity. In addition, after DMC treatment the level of Annexin-/PI+ cells were 
comparable to untreated cells. Together with the results obtained using MTS assays, these 
results suggest that treating cells with concentrations up to 50 µM DMC did not result 
in apoptosis or necrosis in these cells, contrasting with the significant reduction seen 
when using the MTS assay. In order to assess if DMC induced ER stress, expression levels 
of GRP78 and CHOP, two established markers of ER stress, were examined. Consistent 
with the previously described role of DMC in ER-stress induction, Western blot analysis 
showed a clear up-regulation of GRP78 and CHOP upon treatment with 50 µM of DMC 
(figure 3C). 
Next, the effect of combined exposure to rhTRAIL WT and 0, 25 or 50 µM of DMC was 
examined in these differentially TRAIL-responsive GBM cell lines. In this assay, A172 cells 
treated for 24 h with 125 ng/mL rhTRAIL without DMC showed already ~75% reduction in 
cell viability (IC
50
: ~36 ng/mL), which was strongly enhanced after combination with DMC 
(25 µM: ~10%, IC
50
: ~12 ng/mL and 50 µM: ~2%, IC
50
: ~1 ng/mL) (figure 4A). Notably, the cell 
viability of A172 cells was reduced with approximately 86% using only 31.3 ng/mL of rhTRAIL 
figure 2. dR5 overexpression does not enhance TRAIL-induced apoptosis in u87 cells. (A) Flow 
cytometry analysis was performed on U87-control and U87-DR5 cells to measure the cell surface 
expression of TRAIL receptors DR4 and DR5, expressed as the Mean Fluorescence Intensity (MFI) ratio. 
A172 cells were used as a control. (B) Cell viability was assessed after 24 h treatment with 0-1000 ng/mL 
rhTRAIL WT or D269H/E195R using MTS assays. Presented data are representative for three independent 
experiments and mean cell viability levels ± S.E.M. are shown.
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WT in combination with 25 µM of DMC, when compared to TRAIL WT in combination 
with 0 µM DMC, where approximately 47% reduction in cell viability could be attained. 
Therefore, TRAIL sensitivity can be enhanced in A172 cells by co-treatment with DMC. 
U87 cells remained TRAIL-resistant (0 µM: ~99%), and although the single treatment with 
DMC was able to lower the cell viability of U87 cells (25 µM: ~87%; 50 µM: 66%), no additive 
or synergistic effects could be found in combination with rhTRAIL WT (figure 4A). Since 
DMC is an analogue of celecoxib, we further tested the sensitivity of these cell lines to 
figure 3. dMC reduces cell viability and induces eR stress in GBM cell lines. (A) Cell viability was 
assessed in a panel of GBM cell lines after 24 h exposure to 0-100 µM of DMC using a MTS assay. Error 
bars represent S.E.M. of three independent experiments. (B) A172 and U87 cells were treated with 0, 25 
or 50 µM DMC for 24 h after which apoptosis induction was determined using Annexin V/PI using flow 
cytometry. (C) Treatment of A172 and U87 cells with 0, 25 or 50 µM DMC for 24 h resulted in a dose-
dependent up-regulation of CHOP and GRP78 proteins levels as showed by Western blotting. β-actin 
serves as a loading control. Presented data are representative for at least three independent experiments 
and mean cell viability levels ± S.E.M. are shown.
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celecoxib treatment. A172 and U87 showed similar IC
50
 values of approximately 88 µM 
for both A172 and U87 (supplementary figure 1). Next, DMC or celecoxib were tested 
side-by-side in combination with rhTRAIL WT. Interestingly, the combination of TRAIL/
DMC (IC
50
: ~57 µM) was shown to be more effective than TRAIL/celecoxib (IC
50
: ~88 µM) 
(supplementary figure 2). Since DMC is a more potent ER stress inducer than celecoxib 
and does not target COX-2 [27, 28], these results suggest that ER stress activation is 
closely related to the reduction of cell viability, and subsequently, the enhancement of 
TRAIL-induced cytotoxicity in these cells.
To confirm that the combinatorial effects described above were correlated with 
enhanced apoptosis activity, the effect of DMC on TRAIL-induced caspase cleavage was 
figure 4. Increased TRAIL sensitivity by dMC is caspase-dependent. (A) Cell viability was assessed 
after 24 h co-treatment with rhTRAIL WT (0-250 ng/mL) and 0, 25 or 50 µM DMC using a MTS assay. Error 
bars represent S.E.M. of three independent experiments. (B) Western blot analysis of A172 (5 h) and U87 
(24 h) cells treated with either rhTRAIL WT (0, 10 or 100 ng/mL) and/or DMC (0, 25 or 50 µM) for caspase-
8, -9, -3 and PARP. β-actin served as a loading control.
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further analysed. Figure 4B shows that after 5 h treatment, A172 cells display a significant 
activation of the caspases-8, -9, -3 and PARP cleavage when exposed to rhTRAIL WT alone, 
and enhanced cleavage when combined with DMC. Treatment with 100 ng/mL of rhTRAIL 
WT and 50 µM DMC resulted in massive cell death in A172 cells. Notably, DMC alone did not 
induce any activation of downstream apoptosis-related proteins, as indicated by a lack 
of caspase activation or PARP cleavage, and in agreement with our earlier observations 
using Annexin V staining assays (figure 3B). Furthermore, acridine orange staining of 
DMC-treated cells showed no evidence of nuclear condensation and nuclear/cellular 
fragmentation, as shown after rhTRAIL WT treatment in A172 cells, but it does appear that 
DMC reduces cell proliferation, especially in A172 cells (figure 5). Notably, in U87 cells 
the combined treatment of rhTRAIL WT with 50 µM DMC led to activation of the initiator 
pro-caspase-8 but no subsequent pro-caspase-9, -3 or PARP cleavage. Treatment of U87 
cells with both TRAIL WT and DMC resulted in the down-regulation of pro-caspase-3 in 
this cell line (figure 4B). Finally, the effect of combined exposure to rhTRAIL WT and DMC 
was also examined in U87-control and U87-DR5 cells, with no significant effect of DMC on 
TRAIL-sensitivity being observed for these cell lines (supplementary figure 3).
dMC down-regulates the anti-apoptotic protein survivin in A172 and u87 cells
Previous studies have reported that ER stress can stimulate apoptosis induction not only 
by up-regulating pro-apoptotic proteins, such as DR5, but also by down-regulating anti-
apoptotic proteins, such as c-FLIP [17-20], Bcl-2 [18, 37, 38] and survivin [18, 23]. Treatment 
with sub-toxic or toxic concentrations of DMC did not affect the level of TRAIL receptors on 
the surface of both A172 and U87 cells (figure 6A). Interestingly, Western Blot analysis showed 
that DMC treatment resulted in a significant down-regulation of survivin levels in both cell 
lines (figure 6B). Furthermore, c-FLIP expression levels were slightly down-regulated in U87 
when treating these cells with DMC. Finally, DMC treatment did not increase the expression 
of DR5 or reduce the expression of the anti-apoptotic protein Bcl-2.
enhancement of TRAIL sensitivity in A172 cells by survivin siRnA
In order to determine if down-regulation of survivin by DMC could explain the increase in 
TRAIL sensitivity observed in A172 cells, its expression was selectively silenced using a siRNA 
approach. Figure 7A shows efficient down-regulation of survivin upon siRNA transfection, 
which resulted in apoptosis activation as indicated by PARP cleavage. Interestingly, the 
addition of only 10 ng/mL rhTRAIL WT enhanced PARP cleavage in survivin knockdown 
cells (figure 7A), whereas the addition of D269H/E195R resulted in massive cell death, such 
that an insufficient amount of lysate could be prepared. Finally, analysis of cell viability 
upon TRAIL treatment in non-transfected, control-siRNA and survivin-siRNA treated cells 
indicate that the down-regulation of survivin slightly increased rhTRAIL WT- and rhTRAIL 
D269H/E195R-mediated apoptosis in A172 at low concentrations, when compared to both 
untransfected and control-siRNA treated cells (figure 7B).
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figure 5. dMC reduces proliferation in GBM cells. Acridine orange staining was used to visualize 
apoptosis in A172 (A) and U87 (B). Cells were treated with 0, 10 or 100 ng/mL rhTRAIL WT and 0, 25 or 
50 µM DMC. After 24 h, cells were stained using acridine orange dye.
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figure 6. dMC mainly down-regulates the anti-apoptotic protein survivin. (A) Flow cytometry 
analysis was performed after 24 h of 0, 25 or 50 µM DMC treatment to measure the cell surface expression 
of TRAIL receptors in A172 and U87 cells, expressed as the Mean Fluorescence Intensity (MFI) ratio. Error 
bars represent S.E.M. of three independent experiments. (B) Western blot analysis of A172 (5 h) and U87 
(24 h) cells treated with either rhTRAIL WT (0, 10 or 100 ng/mL) and/or DMC (0, 25 or 50 µM). C-FLIP, Bcl-2 
and survivin protein expression levels were tested. β-actin served as a loading control. Presented data 
are representative for at least two independent experiments.
dIsCussIon
TRAIL is a promising anticancer therapeutic agent that is able to induce apoptosis in various 
tumour cells while leaving normal cells unharmed [4, 5]. Currently, many GBM cells show 
resistance to TRAIL-induced apoptosis due to various reasons, including low expression of 
DR4 and DR5 [9, 10], the up-regulation of anti-apoptotic proteins such as c-FLIP, Bcl-2 and 
survivin [9, 11-14], or the down-regulation of critical pro-apoptotic proteins such as caspase-8 
and Bak [9, 12, 15, 16]. Recently, the use of ER stress inducers, like DMC, have raised great 
interest as potential anti-cancer agents and sensitizers for TRAIL-based therapies, since ER 
stress was reported to down-regulate important anti-apoptotic proteins, including c-FLIP 
[17-20], Bcl-2 [18, 37, 38] and survivin [18, 23]. Here, we investigated the cell death induction 
properties of DMC in a panel of GBM cells, as well as the potential of DMC in enhancing 
TRAIL-induced apoptosis in TRAIL-resistant and -sensitive GBM cells.
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We find that A172 and U87 express predominantly DR5 but not DR4 on their surface, 
with different levels of expression observed between cell lines (figure 1A). The DR5-high 
expressing A172 cells were especially sensitive to apoptosis induced by the rhTRAIL variant 
D269H/E195R, while U87 cells were resistant to apoptosis induction via both DR4 and DR5 
(figure 1B). Interestingly, the ectopic overexpression of DR5 in U87 cells does not lead to 
enhancement of TRAIL sensitivity, indicating that lowered surface death receptor levels 
is not the main reason for TRAIL resistance in this cell line, and further suggesting that 
downstream processes prevent the activation of the TRAIL-apoptosis cascade (figure 2A,B).
We further studied the impact of ER stress inducer DMC, alone and in the context of 
TRAIL-mediated apoptosis. We demonstrate that DMC is able to efficiently reduce the cell 
viability of a panel of GBM cells and induce ER stress as seen by the up-regulation of the 
ER stress proteins GRP78 and CHOP in A172 and U87 cells (figure 3). Although A172 and U87 
show a clear dose-dependent reduction in cell viability upon treatment with DMC, this is 
not accompanied by an enhancement of Annexin V or PI staining in these two cell lines 
(figure 3B), the activation of caspases (figure 4B) or the appearance of nuclear condensation 
(figure 5), indicating that DMC did not trigger apoptosis or necrosis in these GBM cells after 
24 hours incubation using the mentioned concentrations. However, looking at figure 5, it 
appears that DMC is reducing proliferation rates, especially in A172 cells.
figure 7. sensitivity of A172 to TRAIL-induced apoptosis is slightly enhanced by down-regulation 
of survivin. (A) Western blot analysis of survivin siRNA transfected A172 cells treated with or without 
10 ng/mL rhTRAIL WT or rhTRAIL D269H/E195R for 5 h. Lysates were tested for survivin down-regulation 
and apoptosis induction by PARP cleavage. β-actin served as a loading control. (B) A172 cells transfected 
with survivin siRNA were treated with 0-100 ng/mL rhTRAIL WT or rhTRAIL D269H/E195R. Cell viability was 
assessed after 24 h using MTS assay. The graphs are corrected for control or survivin knockdown induced 
cytotoxicity. Presented data are representative for at least three independent experiments and mean cell 
viability levels ± S.E.M. are shown.
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The combination of rhTRAIL WT or the DR5-specific variant with middle or high 
concentrations of DMC resulted in a significant increase in apoptosis induction in 
A172, leading to nearly complete apoptosis induction at very low concentrations of the 
ligand rhTRAIL when combined with DMC (figure 4 and 5). Although the up-regulation 
of DR5 [17-22, 37] or down-regulation of c-FLIP [17-20], Bcl-2 [18, 37, 38] or survivin [18, 
23, 29] have been previously described as molecular mechanisms accountable for the 
sensitizing effect of ER stress induction (or DMC treatment on TRAIL-induced apoptosis), 
we only detected down-regulation of survivin in these cell lines upon treatment with 
DMC (figure  6). Survivin down-regulation induced apoptosis in A172 cells and only 
slightly affected rhTRAIL WT and D269H/E195R sensitivity in this cell line (figure  7). 
The fact that survivin-mediated knockdown only partially affects the sensitivity of this 
cell line towards TRAIL-induced apoptosis indicate that other mechanisms, perhaps 
ER-stress independent, may further contribute to the synergistic effects observed for 
TRAIL in combination with DMC. Furthermore, the depletion of survivin by siRNA led to 
the induction of apoptosis in A172, contrasting to the lack of clear apoptosis-inducing 
activity by the ER stress agent DMC.
Recently, Kardosh et al. have assigned the anti-tumour effect of DMC to the 
inhibition of cell proliferation through the down-regulation of cyclins A and B and 
the consequent loss of cyclin-dependent kinase activity. In that report, the authors 
have demonstrated the dose-dependent down-regulation of cell cycle-regulatory 
proteins in the presence of 0, 25 and 50 µM of DMC or celecoxib [40]. A recent study 
by Ehrhardt et al. described the increased sensitivity to TRAIL-induced apoptosis in 
cell cycle-arrested tumour cells [42]. These findings, combined with our observation 
that synergistic effects can be observed when using DMC in combination with TRAIL 
in a subset of GBM cells, give us further insight in the pleiotropic nature of this class of 
compounds and their potential effects in further enhancing or sensitizing cancer cells 
to TRAIL-induced apoptosis.
In contrast to the results obtained for A172 cells, DMC was not sufficient to circumvent 
TRAIL-resistance in U87 and DR5 overexpressing U87 cells, even when both c-FLIP and 
survivin down-regulation was observed after treatment with 50 µM DMC. While the 
combined treatment of rhTRAIL WT with 50 µM DMC led to a clear activation of pro-
caspase-8, subsequent cleavage of pro-caspase-9, -3 and PARP could not be detected. 
Intriguingly, combination treatment of U87 led to a significant reduction in the expression 
of pro-caspase-3. Yet, U87 cells remain resistant to TRAIL, likely due to reduced pro-
caspase-3 expression levels or other persistent downstream mechanisms of resistance 
that are in place in this particular cell line. Although several mechanisms of caspase-3 
down-regulation have been previously described [43-46], it is currently unclear how 
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ConCLusIons
Our data clearly shows DMC might be a potential anti-cancer agent for the treatment of 
GBM, that can further potentiate TRAIL-induced apoptosis in a subset of GBM. DMC alone 
appears to effectively decrease the cell viability of a panel of GBM cells. Importantly, 
reduction of cell viability by 24 h treatment with DMC did not lead to apoptosis or 
necrosis, but seems be due to reduced proliferation. We find that the DMC-mediated 
down-regulation of survivin partially accounts for the mechanism of TRAIL sensitization 
in A172 cells. As rhTRAIL warrants high tumour selectivity and sub-toxic concentrations of 
DMC further sensitize these cancer cells to TRAIL, it will be important to assess how other 
cells, especially primary cells, respond to such combination modalities. Additionally, the 
anti-tumorigenic properties of DMC alone and in the context of co-treatment will require 
further in vitro and in vivo studies, especially considering how effective cancer-specific 
apoptosis induction may provide therapeutic opportunities for the treatment of GBM as 
well as many other cancers.
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suPPLeMenTARy InfoRMATIon
supplementary figure 1. A172 and u87 cells are less sensitive to celecoxib when compared to dMC. 
Cell viability was assessed after 24 h exposure of A172 (A) or U87 (B) to 0-100 µM of CXB or DMC using a 
MTS assay. Error bars represent S.E.M. of three independent experiments.
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supplementary figure 2. dMC is more potent in reducing cell viability when combined with TRAIL 
than celecoxib. Cell viability was assessed after 24 h co-treatment of A172 (A) or U87 (B) with rhTRAIL WT 
(0-250 ng/mL) and 0, 25 or 50 µM celecoxib (CXB) or DMC using MTS assays. Error bars represent S.E.M. 
of three independent experiments.
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supplementary figure 3. dR5 overexpression in u87 cells did not enhance sensitivity to TRAIL in 
combination with dMC. Viability was assessed after 24 h co-treatment of U87-control (A) or U87-DR5 
(B) with 0-1000 ng/mL rhTRAIL WT and 0, 25 or 50 µM DMC using MTS assays. Presented data are 
representative for three independent experiments and mean cell viability levels ± S.E.M. are shown.

